Todd J. Schwedt

Todd J. Schwedt

Auto-generated profile, based on publicly available information

Todd J. Schwedt

Department of Neurology Mayo Clinic Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2007 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
LCLeonard H. Calabrese
Leonard H. Calabrese
DDDavid W. Dodick
David W. Dodick
TSTodd J. Schwedt
Todd J. Schwedt
ASAneesh B. Singhal
Aneesh B. Singhal
Reversible cerebral vasoconstriction syndromes (RCVS) comprise a group of diverse conditions, all characterized by reversible multifocal narrowing of the cerebral arteries heralded by sudden (thunderclap), severe headaches with or without associated neurologic deficits. Reversible cerebral vasoconstriction syndromes are clinically important because they affect young persons and can be complicated by ischemic or hemorrhagic strokes. The differential diagnosis of RCVS includes conditions associated with thunderclap headache and conditions that cause irreversible or progressive cerebral artery narrowing, such as intracranial atherosclerosis and cerebral vasculitis. Misdiagnosis as primary cerebral vasculitis and aneurysmal subarachnoid hemorrhage is common because of overlapping clinical and angiographic features. However, unlike these more ominous conditions, RCVS is usually self-limited: Resolution of headaches and vasoconstriction occurs over a period of days to weeks. In this review, we describe our current understanding of RCVS; summarize its key clinical, laboratory, and imaging features; and discuss strategies for diagnostic evaluation and treatment.

24 January 2012 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
PTPeer Tfelt-Hansen
Peer Tfelt-Hansen
JPJulio Pascual
Julio Pascual
NRNabih Ramadan
Nabih Ramadan
CDCarl Dahlöf
Carl Dahlöf
DDDomenico D’Amico
Domenico D’Amico
TSTodd Schwedt
Todd Schwedt

1 January 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
TSTodd J Schwedt
Todd J Schwedt
CCChia-Chun Chiang
Chia-Chun Chiang
CCCatherine D Chong
Catherine D Chong
DDDavid W Dodick
David W Dodick

24 March 2014 in BMJ
Verified
Journal Article
Closed access
PDF file
TSTodd J Schwedt
Todd J Schwedt
Chronic migraine is a disabling neurologic condition that affects 2% of the general population. Patients with chronic migraine have headaches on at least 15 days a month, with at least eight days a month on which their headaches and associated symptoms meet diagnostic criteria for migraine. Chronic migraine places an enormous burden on patients owing to frequent headaches; hypersensitivity to visual, auditory, and olfactory stimuli; nausea; and vomiting. It also affects society through direct and indirect medical costs. Chronic migraine typically develops after a slow increase in headache frequency over months to years. Several factors are associated with an increased risk of transforming to chronic migraine. The diagnosis requires a carefully performed patient interview and neurologic examination, sometimes combined with additional diagnostic tests, to differentiate chronic migraine from secondary headache disorders and other primary chronic headaches of long duration. Treatment takes a multifaceted approach that may include risk factor modification, avoidance of migraine triggers, drug and non-drug based prophylaxis, and abortive migraine treatment, the frequency of which is limited to avoid drug overuse. This article provides an overview of current knowledge regarding chronic migraine, including epidemiology, risk factors for its development, pathophysiology, diagnosis, management, and guidelines. The future of chronic migraine treatment and research is also discussed.

1 July 2006 in The Lancet Neurology
Verified
Journal Article
Closed access
TSTodd J Schwedt
Todd J Schwedt
MMManjit Singh Matharu
Manjit Singh Matharu
DDDavid W Dodick
David W Dodick

27 November 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
PMPaolo Martelletti
Paolo Martelletti
TSTodd J. Schwedt
Todd J. Schwedt
MLMichel Lantéri-Minet
Michel Lantéri-Minet
RQRebeca Quintana
Rebeca Quintana
VCVeruska Carboni
Veruska Carboni
PVPamela Vo
Pamela Vo
Migraine is associated with many debilitating symptoms that affect daily functioning. My Migraine Voice is a large global cross-sectional study aimed at understanding the full burden and impact of migraine directly from patients suffering from ≥4 monthly migraine days (MMDs) with a history of prophylactic treatment failure. This study was conducted worldwide (31 countries across North and South Americas, Europe, the Middle East and Northern Africa, and the Asia-Pacific region) using an online survey administered to adults with migraine who reported ≥4 MMDs in the 3 months preceding survey administration, with pre-specified criteria of 90% having used preventive migraine treatment (80% with history of ≥1 treatment failure). Prophylactic treatment failure was defined as a reported change in preventive medication by individuals with migraine for any reason, at least once. In total, 11,266 individuals participated in the survey. Seventy-four percent of the participants reported spending time in darkness/isolation due to migraine (average: 19 h/month). While 85% of all respondents reported negative aspects of living with migraine (feeling helpless, depressed, not understood), sleeping difficulties (83%), and fear of the next attack (55%), 57% shared ≥1 positive aspect (learning to cope, becoming a stronger person). Forty-nine percent reported feeling limited in daily activities throughout all migraine phases. Migraine impact on professional, private, or social domains was reported by 87% of respondents (51% in all domains). In the previous 12 months, 38% of respondents had visited the emergency department (average: 3.3 visits), whereas 23% stayed in hospital overnight (average: 3.2 nights) due to migraine. The burden of migraine is substantial among this cohort of individuals with at least 4 migraine days per month and for whom at least 1 preventive migraine treatment had failed. Interestingly, respondents reported some positive aspects in their migraine journey; the greater resilience and strength brought on by coping with migraine suggests that if future treatments could address existing unmet needs, these individuals with migraine will be able to maximize their contribution to society.